Valuation: Epigenomics AG

Market Cap 798K 921K 747K 682K 1.28M 87.83M 1.3M 8.76M 3.43M 43.96M 3.46M 3.38M 147M P/E 2024
-0.29x
P/E 2025 -2.51x
Enterprise Value 11.77M 13.58M 11.01M 10.05M 18.91M 1.29B 19.23M 129M 50.6M 648M 50.97M 49.86M 2.16B EV / Sales 2024
-
EV / Sales 2025 490x
Free-Float
70.75%
Yield 2024 *
-
Yield 2025 -
1 day+31.87%
1 week+33.33%
Current month+27.66%
1 month+37.93%
3 months+29.03%
6 months+37.93%
Current year+33.33%
1 week 0.91
Extreme 0.91
1.56
1 month 0.87
Extreme 0.87
1.56
Current year 0.84
Extreme 0.84
1.56
1 year 0.84
Extreme 0.84
1.59
3 years 0.5
Extreme 0.5
3.65
5 years 0.5
Extreme 0.5
25.88
10 years 0.5
Extreme 0.5
1,187.36
Manager TitleAgeSince
Investor Relations Contact - -
Corporate Officer/Principal 55 2024-01-31
Director TitleAgeSince
Chairman 58 2023-02-28
Director/Board Member 55 2020-05-31
Director/Board Member 56 2024-02-04
Date Insider Type Main position Quantity % Market Cap.
12/29/22 Buy

Chief Financial Officer

2,000 0.0122%
9/7/21 Sell

Director

7,790 0.0637%
2/1/21 Buy

Chairman

6,355 0.1079%
Change 5-day change 1-year change 3-year change Capi.($)
+31.87%+33.33%+36.36%-63.91% 922K
+0.47%+3.95%+110.04%+305.08% 4.06B
+0.33%-0.18%+65.51%+84.19% 3.72B
+0.08%+47.71%+226.90%-8.78% 2.9B
+1.78%+1.38%+305.61%+436.40% 2.44B
+1.43%+8.61%-20.91%-31.40% 2.31B
+4.22%+5.54%+9.93% - 1.31B
+5.85%+21.91%+8.32%+40.30% 988M
-5.02%-9.64%+182.04%-43.81% 904M
+5.70%+10.16%-32.72%+0.34% 541M
Average +4.66%+16.87%+89.11%+79.82% 1.92B
Weighted average by Cap. +1.09%+23.38%+115.37%+140.90%

Financials

2024 2025
Net sales - 24K 27.69K 22.47K 20.5K 38.58K 2.64M 39.23K 263K 103K 1.32M 104K 102K 4.41M
Net income -3.35M -3.87M -3.14M -2.86M -5.39M -369M -5.48M -36.79M -14.42M -185M -14.52M -14.21M -616M -314K -362K -294K -268K -505K -34.56M -513K -3.45M -1.35M -17.3M -1.36M -1.33M -57.71M
Net Debt 10.46M 12.06M 9.79M 8.93M 16.81M 1.15B 17.09M 115M 44.97M 576M 45.3M 44.31M 1.92B 10.97M 12.66M 10.27M 9.37M 17.63M 1.21B 17.92M 120M 47.17M 604M 47.52M 46.48M 2.02B
Logo Epigenomics AG
Epigenomics AG is a Germany-based molecular diagnostics company focused on blood-based detection, prognosis and monitoring of cancers using deoxyribonucleic acid (DNA) methylation technology. It develops and commercializes blood-based diagnostic products across multiple cancer indications. The Company's main product is Epi proColon, a blood test for colorectal cancer screening. Along with the blood-based tests the Company offers services related to research, product development, regulatory approval and manufacturing of in-vitro diagnostic (IVD) products. It also offers Epi proLung, a blood-based test that detects the presence of lung cancer in blood plasma. The Company is present in Europe and the United States.
Employees
3
Date Price Change Volume
26-08-11 1.200 +31.87% 342
26-08-10 €0.9100 0.00% 0
26-08-07 €0.9100 -1.09% 0
26-08-06 €0.9200 0.00% 100
26-08-05 €0.9200 +2.22% 7

Annual profits - Rate of surprise